Clearside Biomedical (CLSD) Reports In-Line Q4 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $306 thousand versus the consensus estimate of $130.14 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• U.S. sees 80%-85% chance Iran deal will be signed - Bloomberg
• Schwab's May activity shows margin loans nearly double